2026-10-19T01:10:04Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/requestoai:ebyu-rdlopen.rawdatalibrary.net:ebyu/168842026-10-18T20:41:06Zopenairedrivercom_ebyu_10000col_ebyu_10001Role of Oxidant and Proinflammatory Cytokines and the Effect of Leflunomide in the Pathogenesis of Ovarian IschemiaReperfusion InjuryIsaoglu, UnalUyar, Elif EsraSahin, NurullahBulut, SevalMammadov, RenadYilmaz, Betul KalkanGunay, MuratMendil, Ali SefaSuleyman, HalisLeflunomideischemia-reperfusionoxidative stressinflammationovarian damageratISCHEMIA-REPERFUSION INJURYISCHEMIA/REPERFUSION INJURYPharmacology & PharmacyBackground and Objective: Ischemia-reperfusion (IR) causes tissue damage by inducing oxidative stress and inflammation. In this study, the protective ability of leflunomide, which is reputed to have antioxidant and anti-inflammatory effects, against IR-induced ovarian damage in rats was researched. Materials and Methods: Twenty-four albino Wistar female rats were divided into 4 groups of six each: Healthy (HG), sham-operated (SOG),ovarian IR (OIR) and leflunomide+ovarian IR (LOIR).One hour beforethe IR procedure, the LOIRgroup received 10 mg/kg leflunomide orally. Ovaries of rats in OIR and LOIR groups were subjected to 3 hrs ischaemia and 6 hrs reperfusion. For six days, leflunomide were implemented once a day. On day seven, the animals were euthanized and their ovaries were collected. The tissues were examined biochemically and histopathologically. Results: Leflunomide treatment significantly suppressed IR-induced rise in malondialdehyde (MDA),Tumor Necrosis Factor-Alpha (TNF-) and Interleukin 6 (IL-6) and the decline in Total Glutathione (tGSH), superoxide dismutase (SOD) and catalase (CAT) (p<0.001). Severe stromal hemorrhage, edema and follicular hemorrhage were noted in the ovaries of the IR group. Leflunomide treatment significantly prevented IR-induced ovarian tissue damage (p<0.05). Conclusion: Leflunomide could protect the ovaries with antioxidant and anti-inflammatory activity in ovarian IR injury.ASIAN NETWORK SCIENTIFIC INFORMATION-ANSINET2024Articlehttps://rdlopen.rawdatalibrary.net/r/ebyu/16884https://doi.org/10.3923/ijp.2024.1440.14471811-7775enINTERNATIONAL JOURNAL OF PHARMACOLOGYinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/16884